| Drug Name |
Levalbuterol tartrate |
| Drug ID |
BADD_D01264 |
| Description |
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
[Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). |
| Indications and Usage |
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB13139
|
| KEGG ID |
D04703
|
| MeSH ID |
D064412
|
| PubChem ID |
10349032
|
| TTD Drug ID |
D02ZJI
|
| NDC Product Code |
50384-4188; 63402-510; 69988-0045; 63187-876; 0591-2927; 63629-8822 |
| UNII |
ADS4I3E22M
|
| Synonyms |
Levalbuterol | Xopenex | Levalbuterol Hydrochloride | Hydrochloride, Levalbuterol | Levosalbutamol Hydrochloride | Hydrochloride, Levosalbutamol |
